Acorda celebrates an FDA OK — so does that make them a takeover target?

Late Friday, with the government shutdown looming, the biotech reported that the FDA has approved their inhaled levodopa therapy Inbrija for Parkinson’s patients, putting the company on a short path to a crucially needed market launch.

Ron Cohen, Acorda CEO

Acorda $ACOR had been looking at a PDUFA date in early January. But with the FDA racking up a record number of approvals this year — and its third on Friday — the company was given a little bit of an added edge for its 2019 rollout.

They need it.

The FDA held up their decision on Inbrija twice, first with a refuse-to-file on the application and later with an extension on the original PDUFA date. Meanwhile, Acorda lost patent protection on its only marketed product, Ampyra, making Inbrija a bridge to its ability to stay in business.

Paul Matteis

The big question for some of the analysts covering the company — after a big sigh of relief on the approval — is whether Acorda with its newly approved therapy gets marked out for a takeover.

Paul Matteis at Stifel put the 2022 sales consensus at $300 million, marking this as a possible takeout drug in a busy market — though well short of blockbuster status. 

Acorda’s shares jumped 5% in pre-market trading Monday.

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 51,100+ biopharma pros who read Endpoints News by email every day.

Free Subscription

VP Oncology Biology
Skyhawk Therapeutics Waltham, MA
Director Process Development
Elektroki Boston, MA
Director Process Development
Elektroki Boston, MA
Research Scientist - Immunology
Recursion Pharmaceuticals Salt Lake City, UT

Visit Endpoints Careers ->